TRAIL与顺铂联合应用对喉鳞癌细胞Hep-2的体外作用  

Effects of TRAIL combined with cisplatin on Hep-2 laryngeal squamous carcinoma in vitro

作　　者：张明[1] 周梁[1] 程磊[1] 田洁[2] 

机构地区：[1]复旦大学附属眼耳鼻喉科医院耳鼻喉科,上海200031 [2]复旦大学附属眼耳鼻喉科医院中心实验室,上海200031

出　　处：《肿瘤》2007年第7期535-537,541,共4页Tumor

摘　　要：目的:探讨肿瘤坏死因子相关诱导凋亡配体(tumornecrosis factor-related apoptosis-inducing ligand,TRAIL)与顺铂联合应用对喉鳞癌细胞Hep-2的抑制作用。方法:CCK-8测定TRAIL和顺铂对Hep-2细胞生长的抑制率;流式细胞术检测细胞表面TRAIL受体的表达及细胞凋亡。结果:Hep-2细胞对TRAIL诱导的凋亡不敏感,顺铂通过上调细胞表面死亡受体的表达而增强Hep-2细胞对TRAIL的敏感性。结论:顺铂可使Hep-2细胞克服对TRAIL的耐受性,两者具有协同作用,有望应用于喉癌的临床治疗。Objective：To investigate the inhibitory effects of tumor necrosis factor-related apoptosis-inducing ligand （TRAIL） combined with cisplatin on laryngeal squamous carcinoma cell line Hep-2. Methods： Hep-2 cells were treated with TRAIL alone or in combination with cisplatin at different concentrations. The inhibition rate was measured by CCK-8 assay. The apoptotic rate of Hep-2 cells and the expressions of DR4, DRS, DcR1, and DcR2 in Hep-2 cells were detected by flow cytometry analysis. Results： Hep-2 cells were resistant to apoptosis induced by TRAIL. Cisplatin could enhance the sensitivity of Hep-2 cells to TRAIL by up-regulating the expressions of TRAIL death receptors on the surface of Hep-2 cells membrane. Conclusion： Cisplatin can overcome the resistance of Hep-2 cells to TRAIL. TRAIL and cisplatin has synergistic anti-tumor effects. The combination therapy may have a promising agent for clinical treatment of laryngeal squamous carcinoma.

关 键 词：喉肿瘤 肿瘤坏死因子相关诱导凋亡配体 顺铂 

分 类 号：R739.65[医药卫生—肿瘤]